Evidence map›Paper›PMID 39115699›Full record

ArticleMolecular biology reports2024

XRCC1 and XPD polymorphisms: clinical outcomes and risk of prostate cancer in Bangladeshi population.

Nafisa Ahmed, Md Ariful Islam, M Mahboob Hossain, Yearul Kabir

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nafisa AhmedDepartment of Mathematics & Natural Sciences, School of Data and Sciences, BRAC University, Dhaka, Bangladesh.ORCID http://orcid.org/0000-0001-5584-0910
Md Ariful IslamDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, 1000, Bangladesh.ORCID http://orcid.org/0000-0003-3565-4891
M Mahboob HossainDepartment of Mathematics & Natural Sciences, School of Data and Sciences, BRAC University, Dhaka, Bangladesh.ORCID http://orcid.org/0000-0001-8307-0028
Yearul KabirDepartment of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, 1000, Bangladesh. ykabir@du.ac.bd.ORCID http://orcid.org/0000-0002-0242-9199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Bangladesh, only a fraction of prostate cancer patients are diagnosed annually due to lack of symptom awareness and screening challenges, resulting in high mortality. Aiming to improve screening methods, we evaluated X-ray cross-complementing gene 1 (XRCC1) Arg194Gln and Xeroderma pigmentosum group D (XPD) Lys751Gln polymorphisms to determine their relevance as potential markers for predicting prostate cancer risk, severity and clinical parameters in Bangladeshi population. METHODS AND

resultsThis study included 132 prostate cancer patients and 135 healthy controls. Genotype analysis was done from blood samples by the PCR-RFLP method. The XRCC1 Trp/Trp genotype was associated with prostate cancer (OR

conclusionOur findings suggest that XRCC1 screening may be used as a biomarker for prostate cancer to improve early diagnosis in Bangladesh.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideProstatic NeoplasmsXeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1AgedBangladeshCase-Control StudiesDNA-Binding ProteinsGenotypeHumansMaleMiddle AgedRisk FactorsDNA-Binding ProteinsERCC2 protein, humanXeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanDNA repair genesPolymorphismProstate CancerXPDXRCC1

Identifiers

PMID39115699

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.